| Primary |
| Type 2 Diabetes Mellitus |
58.7% |
| Diabetes Mellitus |
16.7% |
| Hypertension |
5.5% |
| Insulin-requiring Type 2 Diabetes Mellitus |
3.3% |
| Pain |
2.1% |
| Blood Cholesterol |
1.5% |
| Coronary Angioplasty |
1.5% |
| Blood Cholesterol Increased |
1.2% |
| Blood Potassium Increased |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Cardiac Disorder |
0.9% |
| Hyperlipidaemia |
0.9% |
| Prophylaxis |
0.9% |
| Convulsion |
0.6% |
| Coronary Artery Disease |
0.6% |
| Diabetic Neuropathy |
0.6% |
| Dyslipidaemia |
0.6% |
| Dyspepsia |
0.6% |
| Headache |
0.6% |
| Hormone Replacement Therapy |
0.6% |
|
| Product Quality Issue |
22.6% |
| Weight Decreased |
22.6% |
| Blood Glucose Increased |
8.2% |
| Nausea |
6.7% |
| Underdose |
5.1% |
| Vomiting |
5.1% |
| Drug Ineffective |
3.6% |
| Circumstance Or Information Capable Of Leading To Medication Error |
3.1% |
| Drug Prescribing Error |
3.1% |
| Pancreatic Carcinoma |
2.6% |
| Pancreatitis Acute |
2.6% |
| Malaise |
2.1% |
| Wrong Technique In Drug Usage Process |
2.1% |
| Drug Dose Omission |
1.5% |
| Injection Site Haemorrhage |
1.5% |
| Injection Site Pain |
1.5% |
| Overdose |
1.5% |
| Pancreatic Carcinoma Metastatic |
1.5% |
| Pancreatitis |
1.5% |
| Pancreatitis Relapsing |
1.5% |
|
| Secondary |
| Type 2 Diabetes Mellitus |
69.0% |
| Insulin-requiring Type 2 Diabetes Mellitus |
11.8% |
| Diabetes Mellitus |
4.2% |
| Hypertension |
1.9% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Pain |
1.4% |
| Hypothyroidism |
1.2% |
| Blood Cholesterol |
1.0% |
| Blood Cholesterol Increased |
1.0% |
| Blood Glucose Increased |
1.0% |
| Cardiac Disorder |
0.9% |
| Diverticulitis |
0.7% |
| Prophylaxis |
0.7% |
| Affective Disorder |
0.5% |
| Blood Pressure |
0.5% |
| Constipation |
0.5% |
| Headache |
0.5% |
| Injection Site Pruritus |
0.5% |
| Pulmonary Embolism |
0.5% |
| Restless Legs Syndrome |
0.5% |
|
| Weight Decreased |
40.0% |
| Weight Increased |
8.8% |
| Nausea |
8.0% |
| Off Label Use |
8.0% |
| Vomiting |
5.6% |
| Injection Site Nodule |
4.8% |
| Blood Glucose Increased |
4.0% |
| Pancreatitis |
3.2% |
| Injection Site Haemorrhage |
2.4% |
| Pancreatitis Acute |
2.4% |
| Urticaria |
2.4% |
| Hepatic Enzyme Increased |
1.6% |
| Renal Failure |
1.6% |
| Tremor |
1.6% |
| Visual Impairment |
1.6% |
| Colon Cancer Metastatic |
0.8% |
| Gastrointestinal Sounds Abnormal |
0.8% |
| Hyperhidrosis |
0.8% |
| Increased Appetite |
0.8% |
| Injection Site Pain |
0.8% |
|
| Concomitant |
| Type 2 Diabetes Mellitus |
81.0% |
| Insulin-requiring Type 2 Diabetes Mellitus |
19.0% |
|
| Injection Site Pain |
42.9% |
| Weight Decreased |
28.6% |
| Injection Site Haemorrhage |
14.3% |
| Underdose |
14.3% |
|
